Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06334016 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
A Early Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT06334016: Clinical Trial Early Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT06334016 is a Early Phase 1 study that has not yet begun recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 60 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06334016, a Early Phase 1 study, has not yet begun recruiting, sponsored by Roswell Park Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.
Primary Outcome
Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- DRUG Placebo Administration
- DRUG Nicotine
- DRUG Cannabis sativa Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-03-01 |
| Phase | Early Phase 1 |
What is known before NCT06334016 opens enrollment
NCT06334016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06334016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06334016 about?
NCT06334016 is a clinical study titled "Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream". This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration...
What is the current status of trial NCT06334016?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2026-07-15. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT06334016?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Placebo Administration (DRUG), Nicotine (DRUG), Cannabis sativa Extract (DRUG).
Who is sponsoring clinical trial NCT06334016?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06334016's enrollment target sits among peer trials
60 403rd of 2000 higher than 1,564 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI